2016 Eli Lilly and Company Product Pipeline Review

The report provides comprehensive information on the therapeutics under development by Eli Lilly and Company, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Get discount on this research report at http://www.rnrmarketresearch.com/contacts/discount?rname=521063

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Eli Lilly and Company

- The report provides overview of Eli Lilly and Company including its business description, key facts, and locations and subsidiaries

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report assesses Eli Lilly and Company's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report features Eli Lilly and Company's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Complete research report of 242 pages with TOC is available at http://www.rnrmarketresearch.com/eli-lilly-and-company-product-pipeline-review-2016-market-report.html

Reasons to buy

- Evaluate Eli Lilly and Company's strategic position with total access to detailed information on its product pipeline

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Eli Lilly and Company

- Identify potential new clients or partners in the target demographic

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Eli Lilly and Company's pipeline depth and focus of pipeline therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope